Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Law firm Johnson Fistel is investigating Simulations Plus (NASDAQ: SLP) for potential violations of federal securities laws affecting investors’ losses. The company previously reported Q2 fiscal 2025 results on Apr. 3, 2025 and reiterated full-year revenue guidance of $90M to $93M. The news is primarily a legal/overhang item and may be modestly negative for sentiment around the stock.

Analysis

This is more of a multiple and liquidity event than a near-term earnings event. For a small-cap, high-gross-margin software name like SLP, litigation headlines can trigger mechanical de-rating because many holders own it for quality/recurring-revenue characteristics and will not wait for legal clarity. The key issue is whether this stays as a headline overhang or becomes a signal that prior disclosures, customer retention, or revenue recognition deserve scrutiny.

The second-order effect is valuation dispersion versus peers such as CERT: if the market starts pricing in any accounting risk at all, SLP can trade like a lower-quality software asset even if fundamentals are unchanged. That usually shows up first in the next 1-2 months as depressed multiple expansion, wider bid-ask spreads, and slower institutional sponsorship rather than an immediate hit to cash flow. If no new facts emerge by the next quarterly filing, the stock can mean-revert quickly because the event itself does not impair demand.

The contrarian view is that these investigations are often noise unless they uncover a restatement, a sharp guide-down, or customer attrition. The best falsifier is clean follow-through: stable bookings/ARR, no changes to guidance, and no unusual language in the next 10-Q/8-K. If that holds, the selloff is likely overdone and becomes a trading event rather than a fundamental one.

Key Decisions for Investors

• No high-conviction fundamental short here yet; treat SLP as a watchlist name until the next filing or management commentary confirms whether the probe is purely headline risk or tied to disclosure quality.
• If the stock sells off another 5-10% on no new facts, consider a tactical long only after volume capitulation and confirmation that guidance/booking trends remain intact; upside is a re-rating back toward peer multiples over 1-3 months.
• Relative-value trade: long CERT / short SLP if the market starts applying a litigation discount to the whole pharma-modeling niche; this isolates company-specific legal risk while keeping exposure to the end-market.
• Use a hard stop if SLP closes below the post-headline low and remains there into the next earnings window; that would suggest the market is pricing in more than headline risk and the thesis shifts to fundamental contamination.
• Alert item: if the next 10-Q, 8-K, or earnings call includes language changes around controls, customer concentration, or revenue recognition, treat that as the catalyst for a larger downside repricing rather than the investigation headline itself.